Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: Results from an international multicentre retrospective cohort study

International Journal of Cardiology

Volumn 163, Issue 3, 2013, Pages 320-325

  Fragasso, Gabriele ^a   Rosano, Giuseppe ^b   Baek, Sang Hong ^c   Sisakian, Hamayak ^d   Di Napoli, Pericle ^e   Alberti, Luca ^a   Calori, Giliola ^a   Kang, Seok Min ^f   Sahakyan, Laura ^d   Sanosyan, Armen ^d   Vitale, Cristiana ^b   Marazzi, Giuseppe ^b   Margonato, Alberto ^a   Belardinelli, Romualdo ^g  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c The Catholic University of Korea   (South Korea)

^d YEREVAN STATE MEDICAL UNIVERSITY   (Armenia)

^e SMDN   (Italy)

^f Yonsei University College of Medicine   (South Korea)

^g OSPEDALI RIUNITI   (Italy)

Author keywords

Heart failure; Metabolic therapy; Morbidity; Mortality; Prognosis; Trimetazidine

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LONG ACTING DRUG; NITRATE; TRIMETAZIDINE; CALCIUM CHANNEL BLOCKING AGENT; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; PLACEBO; RENIN INHIBITOR;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; EVENT FREE SURVIVAL; EXERCISE; FATTY ACID OXIDATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PARKINSONISM; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; RISK REDUCTION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DEFIBRILLATION; DRUG EFFICACY; HAZARD RATIO; HOSPITALIZATION; KAPLAN MEIER METHOD; LONG TERM SURVIVAL; MULTICENTER STUDY (TOPIC); NEW YORK HEART ASSOCIATION CLASS; REGRESSION ANALYSIS; SELECTION BIAS; SYMPTOM; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FATTY ACIDS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; INTERNATIONALITY; MALE; MIDDLE AGED; MORBIDITY; OXIDATION-REDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 84874529386     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.09.123     Document Type: Article

References (45)

1. J. Passeron Effectiveness of trimetazidine in stable effort angina due to chronic coronary insufficiency. A double-blind versus placebo study Presse Med 15 1986 1775 1777
2. A.P. Michaelides, G.P. Vyssoulis, P.E. Bonoris, T.K. Psaros, P.D. Papadopoulos, and P.K. Toutouzas Beneficial effects of trimetazidine in men with stable angina under beta-blocker treatment Curr Ther Res 46 1989 565 576
3. S. Levy, and the Group of South of France Investigators Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease Am J Cardiol 76 1995 12B 16B
4. S. Dalla-Volta, G. Maraglino, P. Della-Valentina, P. Viena, and A. Desideri Comparison of trimetazidine with nifedipine in effort angina: a double blind, cross-over study Cardiovasc Drugs Ther 4 1990 853 860
5. J.M. Detry, P. Sellier, S. Pennaforte, D. Cokkinos, H. Dargie, and P. Mathes Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina Br J Clin Pharmacol 37 1994 279 388
6. S. Chierchia, and G. Fragasso Metabolic management of ischaemic heart disease Eur Heart J 14 1993 2 5 (Suppl. G)
7. 31P-NMR spectroscopy in the isolated rat heart Arch Int Pharmacodyn Ther 286 1987 97 110
8. G. Fragasso, G. Perseghin, and F. De Cobelli Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure Eur Heart J 27 2006 942 948
9. D. Lagadic-Gossmann, K. Le Prigent, and D. Feuvray Effects of trimetazidine on pHi in the rat isolated ventricular myocyte Br J Pharmacol 117 1996 831 838
10. 2â regulation by trimetazidine during cardiac cell acidosis Cardiovasc Drugs Ther 1 1988 677 686
11. I. Maridonneau-Parini, and C. Harpey Effects of trimetazidine on membrane damage induced by oxygen free radicals in human red cells Br J Clin Pharmacol 20 1985 148 151
12. L. Kay, C. Finelli, J. Aussedat, C. Guarnieri, and A. Rossi Improvement of long-term preservation of the isolated arrested rat heart by trimetazidine: effects on the energy state and mitochondrial function Am J Cardiol 76 1995 45B 49B
13. E. Fantini, L. Demaison, E. Sentex, A. Grynberg, and P. Athias Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation J Mol Cell Cardiol 26 1994 949 958
14. P.F. Kantor, A. Lucien, R. Kozak, and G.D. Lopaschuk The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase Circ Res 86 2000 580 588
15. L. Brottier, J.L. Barat, C. Combe, B. Boussens, J. Bonnet, and H. Bricaud Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy Eur Heart J 11 1990 207 212
16. C. Lu, P. Dabrowski, G. Fragasso, and S.L. Chierchia Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease: a double-blind, placebo-controlled, crossover study Am J Cardiol 82 1998 898 901
17. R. Belardinelli, and A. Purcaro Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischemic cardiomyopathy Eur Heart J 22 2001 2164 2170
18. G. Fragasso, P.M. Piatti, and L. Monti Short and long term beneficial effects of partial free fatty acid inhibition in diabetic patients with ischemic dilated cardiomyopathy Am Heart J 146 2003 E1 E8
19. C. Vitale, M. Wajngaten, and B. Sposato Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease Eur Heart J 25 2004 1814 1821
20. P. Di Napoli, A.A. Taccardi, and A. Barsotti Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy Heart 91 2005 161 165
21. R. Belardinelli, G. Cianci, M. Gigli, M. Mazzanti, and F. Lacalaprice Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy J Cardiovasc Pharmacol 51 2008 611 615
22. I. Thrainsdottir, H. von Bibra, K. Malmberg, and L. Ryden Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure J Cardiovasc Pharmacol 44 2004 101 108
23. G. Fragasso, A. Palloshi, and P. Puccetti A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with systolic dysfunction heart failure J Am Coll Cardiol 48 2006 992 998
24. H. Sisakian, A. Torgomyan, and A. Barkhudaryan The effect of trimetazidine on left ventricular systolic function and physical tolerance in patients with ischaemic cardiomyopathy Acta Cardiol 62 2007 493 499
25. H. Tuunanen, E. Engblom, and A. Naum Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy Circulation 118 2008 1250 1258
26. G. Fragasso, A. Salerno, and G. Lattuada Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure Heart 97 18 2011 1495 1500
27. D. Gao, N. Ning, X. Niu, G. Hao, and Z. Meng Trimetazidine: a meta-analysis of randomised controlled trials in heart failure Heart 97 2011 278 286
28. L. Zhang, Y. Lu, and H. Jiang Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis J Am Coll Cardiol 59 10 2012 913 922
29. P. Di Napoli, P. Di Giovanni, M.A. Gaeta, A.A. Taccardi, and A. Barsotti Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial J Cardiovasc Pharmacol 50 2007 585 589
30. S.S. Iyengar, and G.M. Rosano Effect of antianginal drugs in stable angina on predicted mortality risk after surviving a myocardial infarction: a preliminary study (METRO) Am J Cardiovasc Drugs 9 2009 293 297
31. G. Fragasso, G. Marinosci, and G. Calori Prognosis of mild/moderate chronic systolic heart failure Int J Cardiol 145 2010 584 586
32. G.M.C. Rosano, C. Vitale, and G. Fragasso Metabolic therapy for patients with diabetes mellitus and coronary artery disease Am J Cardiol 98 2006 14J 18J
33. G. Fragasso Inhibition of free fatty acids metabolism as a therapeutic target in patients with heart failure Int J Clin Pract 61 2007 603 610
34. H. Ashrafian, M.P. Frenneaux, and L.H. Opie Metabolic mechanisms in heart failure Circulation 24 116 2007 434 448
35. E.T. Poehlman, J. Scheffers, S.S. Gottlieb, M.L. Fisher, and P. Vaitekevicius Increased resting metabolic rate in patients with congestive heart failure Ann Intern Med 121 1994 860 862
36. M. Riley, J.S. Elborn, W.R. McKane, N. Bell, C.F. Stanford, and D.P. Nicholls Resting energy expenditure in chronic cardiac failure Clin Sci 80 1991 633 639
37. H.J. Proctor, J. Fry, and R. Harry The metabolic cost of increased respiratory work South Med J 67 1974 1047 1051
38. J.N. Cohn, T.B. Levine, and M.T. Olivari Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure N Engl J Med 311 1984 819 823
39. B. Levine, J. Kalman, L. Mayer, H.M. Fillit, and M. Packer Elevated circulating levels of tumor necrosis factor in severe chronic heart failure N Engl J Med 323 1990 236 241
40. S.D. Anker, K.R. Egerer, H.D. Volk, W.J. Kox, P.A. Poole-Wilson, and A.J. Coats Elevated soluble CD14 receptors and altered cytokines in chronic heart failure Am J Cardiol 79 1997 1426 1430
41. G.D. Lopaschuck, and W.C. Stanley Glucose metabolism in the ischemic heart Circulation 95 1997 313 315
42. L.D. Monti, E. Setola, and G. Fragasso Metabolic and endothelial effects of trimetazidine on forearm muscle in patients with type 2 diabetes and ischemic cardiomyopathy Am J Physiol Endocrinol Metab 290 2006 E54 E59
43. R. Belardinelli, M. Solenghi, L. Volpe, and A. Purcaro Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect Eur Heart J 28 2007 1102 1108
44. H. Taegtmeyer, C.R. Wilson, P. Razeghi, and S. Sharma Metabolic energetics and genetics in the heart Ann N Y Acad Sci 1047 2005 208 218
45. W.H. Tang Metabolic approach in heart failure: rethinking how we translate from theory to clinical practice J Am Coll Cardiol 48 2006 999 1000